1.60
前日終値:
$1.56
開ける:
$1.6
24時間の取引高:
2.06M
Relative Volume:
1.21
時価総額:
$211.37M
収益:
-
当期純損益:
$-67.68M
株価収益率:
-0.9639
EPS:
-1.66
ネットキャッシュフロー:
$-54.24M
1週間 パフォーマンス:
-9.60%
1か月 パフォーマンス:
-22.33%
6か月 パフォーマンス:
-31.33%
1年 パフォーマンス:
-78.35%
Cabaletta Bio Inc Stock (CABA) Company Profile
CABA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CABA
Cabaletta Bio Inc
|
1.60 | 211.37M | 0 | -67.68M | -54.24M | -1.66 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-20 | ダウングレード | Evercore ISI | Outperform → In-line |
2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2024-10-10 | 開始されました | UBS | Buy |
2024-02-05 | 開始されました | Jefferies | Buy |
2023-11-29 | 開始されました | William Blair | Outperform |
2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
2023-10-19 | 開始されました | Stifel | Buy |
2023-09-05 | 開始されました | Citigroup | Buy |
2023-07-18 | 開始されました | Guggenheim | Buy |
2023-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2022-08-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-12-08 | 開始されました | Wells Fargo | Overweight |
2021-10-19 | 再開されました | Morgan Stanley | Overweight |
2021-06-30 | 開始されました | Mizuho | Buy |
2021-01-08 | 開始されました | Chardan Capital Markets | Buy |
2020-10-13 | 開始されました | H.C. Wainwright | Buy |
2019-11-19 | 開始されました | Cowen | Outperform |
2019-11-19 | 開始されました | Evercore ISI | Outperform |
2019-11-19 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Cabaletta Bio Inc (CABA) 最新ニュース
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) PT at $20.33 - MarketBeat
Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces market skepticism - Investing.com Australia
Cabaletta Bio’s SWOT analysis: CAR-T pioneer’s stock faces market skepticism - Investing.com Australia
Cabaletta Bio’s SWOT analysis: CAR-T pioneer’s stock faces market skepticism By Investing.com - Investing.com South Africa
Cantor Fitzgerald Weighs in on Cabaletta Bio FY2026 Earnings - MarketBeat
Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy - MSN
Cabaletta Bio stock price target reiterated on strong clinical data By Investing.com - Investing.com India
Cabaletta Bio stock price target reiterated on strong clinical data - Investing.com
Cabaletta Bio Prices Public Offering to Raise $100 Million - MSN
Cabaletta Bio Announces Public Offering of Common Stock and Warrants - MSN
H.C. Wainwright reiterates buy rating on Cabaletta Bio stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates buy rating on Cabaletta Bio stock - Investing.com Australia
Cabaletta Bio’s (CABA) Buy Rating Reaffirmed at HC Wainwright - Defense World
Analysts Offer Predictions for Cabaletta Bio FY2026 Earnings - Defense World
Cabaletta Bio Launches Public Offering Of Stock And Warrants - Nasdaq
Cabaletta Bio (CABA) Shares Drop 20% After Public Offering Annou - GuruFocus
Cabaletta Bio (CABA) Showcases Promising Rese-cel Data at EULAR 2025 | CABA Stock News - GuruFocus
Cabaletta Bio announces public offering of common stock and warrants By Investing.com - Investing.com South Africa
Cabaletta Bio prices $100 million public offering of shares and warrants By Investing.com - Investing.com South Africa
Cabaletta reports positive clinical data for autoimmune cell therapy By Investing.com - Investing.com South Africa
Cabaletta Bio looks to raise $100M in stock sale to fund cell therapy development - The Business Journals
Cabaletta Bio (CABA) Receives Reiterated Buy Rating from HC Wain - GuruFocus
Cabaletta Bio (CABA) Receives Reiterated Buy Rating from HC Wainwright & Co. | CABA Stock News - GuruFocus
Cabaletta Bio shares CAR-T results in three autoimmune conditions - Endpoints News
Cabaletta Bio Prices Securities Offering; Shares Fall - MarketScreener
Cabaletta Bio stock tumbles after pricing $100 million public offering By Investing.com - Investing.com Nigeria
Cabaletta Bio stock tumbles after pricing $100 million public offering - Investing.com Australia
Cabaletta Bio Announces Pricing of Public Offering of Securities - GuruFocus
Cabaletta Bio prices $100 million public offering of shares and warrants - Investing.com
Cabaletta Bio: Sector Headwinds And Funding Issues, But Also Some Clear Clinical Direction - Seeking Alpha
Cabaletta Bio announces public offering of common stock and warrants - Investing.com
Cabaletta Bio (CABA) Launches Public Offering with Warrants | CABA Stock News - GuruFocus
Cabaletta Bio Announces Proposed Public Offering of Securities | - GuruFocus
Cabaletta Bio Announces Proposed Public Offering of Securities - The Manila Times
Cabaletta Bio Announces Proposed Public Offering of Securities | CABA Stock News - GuruFocus
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in - GuruFocus
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress | CABA Stock News - GuruFocus
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - The Manila Times
Cabaletta reports positive clinical data for autoimmune cell therapy - Investing.com
Breakthrough: New Autoimmune Therapy Achieves Drug-Free Remission in 94% of Trial Patients - Stock Titan
Cabaletta Bio Stockholders Approve Key Proposals - TipRanks
Cabaletta Bio Inc (CABA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):